ELIXIRON IMMUNOTHERAPEUTICS
Elixiron Immunotherapeutics is driven by an international team with a shared vision to produce next-generation immunotherapies. This vision drives our mission to target rare and inflammatory disorders as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain... phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.
ELIXIRON IMMUNOTHERAPEUTICS
Social Links:
Industry:
Biotechnology
Founded:
2017-01-01
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.elixiron.com
Total Employee:
11+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Microsoft Exchange Online Office 365 Mail ASP.NET IIS ASP.NET 4.0 GoDaddy SSL
Current Employees Featured
Founder
Investors List
Alzheimer's Association
Alzheimer's Association investment in Grant - Elixiron Immunotherapeutics
Pangu Venture Capital
Pangu Venture Capital investment in Series A - Elixiron Immunotherapeutics
Mega International Commercial Bank
Mega International Commercial Bank investment in Series A - Elixiron Immunotherapeutics
China Development Industrial Bank (CDIB)
China Development Industrial Bank (CDIB) investment in Series A - Elixiron Immunotherapeutics
DCI Partners
DCI Partners investment in Series A - Elixiron Immunotherapeutics
Fubon Financial Holdings
Fubon Financial Holdings investment in Series A - Elixiron Immunotherapeutics
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation investment in Series A - Elixiron Immunotherapeutics
Official Site Inspections
http://www.elixiron.com Semrush global rank: 7 M Semrush visits lastest month: 646
- Host name: 47.243.30.47
- IP address: 47.243.30.47
- Location: San Mateo United States
- Latitude: 37.5517
- Longitude: -122.33
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94402
